文献速递脊柱脊髓外科神经重症

颈椎脊髓型颈椎病中胶质与轴索损伤的脑脊液生物标志物

Cerebrospinal fluid biomarkers of glial and axonal injury in cervical spondylotic myelopathy.
PubMed 文献 · J Neurosurg Spine · 2021-01-29

本研究分析颈椎脊髓型颈椎病(CSM)患者与对照者的脑脊液生物标志物,并行MRI评估及术前与术后3个月神经功能量表评定。结果显示CSM患者NF-L与GFAP升高,FABP3、sAPPα/β及Aβ38/40/42降低,部分标志物与症状时长及功能评分相关,提示轴索损伤、星形胶质活化与Aβ代谢异常可能参与CSM病理生理并可辅助预后判断。

要点

  • CSM患者脑脊液NF-L与GFAP升高,提示轴索损伤与星形胶质活化。
  • FABP3、sAPPα/β及Aβ38/40/42在CSM患者中降低,Aβ水平与症状时长正相关。
  • 术前NF-L与下肢功能正相关,sAPPα/β与膀胱功能负相关。

核心结论

  • CSM患者脑脊液胶质与轴索损伤、炎症及突触相关生物标志物发生改变,可能反映轴索损伤、星形胶质活化与Aβ代谢异常,并有助于预后判断。

研究设计与样本

  • 纳入连续20例CSM患者(平均年龄67.7±13岁)与63例对照者(平均年龄65.2±14.5岁,p>0.05),用免疫分析法检测脑脊液生物标志物,并以MRI评估脊髓改变。
  • 术前及术后3个月应用ASIA损伤量表、JOACMEQ与EQ-5D问卷评估,p<0.05为差异有统计学意义。

主要发现

  • CSM患者脑脊液NF-L与GFAP浓度高于对照者(p<0.05)。
  • CSM患者FABP3、sAPPα、sAPPβ及Aβ38、Aβ40、Aβ42浓度低于对照者(p<0.05)。
  • Aβ肽水平与症状持续时间呈正相关。
  • 术前JOACMEQ下肢功能与脑脊液NF-L呈正相关,JOACMEQ膀胱功能与sAPPα、sAPPβ呈负相关(p<0.05)。
  • 预后改善(EQ-5D视觉模拟量表差值>20)的患者脑脊液NF-L与FABP3水平更高。

临床怎么用

  • 脑脊液NF-L、GFAP、FABP3及Aβ/sAPP相关标志物可能辅助评估CSM病理生理状态与预后,但尚需更大样本验证。

局限性

  • 样本量较小(20例CSM患者),需更大患者队列验证。
  • 缺乏术后生物标志物数据与术后影像学资料。
  • 随访时间较短(术后3个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Degenerative cervical spondylotic myelopathy (CSM) is a major cause of spinal cord dysfunction with an unpredictable prognosis. Βiomarkers reflecting pathophysiological processes in CSM have been insufficiently investigated. It was hypothesized that preoperative cerebrospinal fluid (CSF) biomarker levels are altered in patients with CSM and correlate with neurological status and outcome. METHODS: CSF biomarkers from patients with CSM and controls were analyzed with immunoassays. Spinal cord changes were evaluated with MRI. The American Spinal Cord Injury Association Impairment Scale, the Japanese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire (JOACMEQ), and the EQ-5D questionnaire were applied prior to and 3 months after surgery. A p value < 0.05 was considered statistically significant. RESULTS: Twenty consecutive CSM patients with a mean age of 67.7 ± 13 years and 63 controls with a mean age of 65.2 ± 14.5 years (p > 0.05) were included in the study. In the CSM subjects, CSF neurofilament light subunit (NF-L) and glial fibrillary acidic protein (GFAP) concentrations were higher (p < 0.05), whereas fatty acid-binding protein 3 (FABP3), soluble amyloid precursor proteins (sAPPα and sAPPβ), and amyloid β (Aβ) peptide (Aβ38, Aβ40, and Aβ42) concentrations were lower than in controls (p < 0.05). Aβ peptide levels correlated positively with symptom duration. Preoperative JOACMEQ lower extremity function and CSF NF-L levels correlated positively, and the JOACMEQ bladder function correlated negatively with sAPPα and sAPPβ (p < 0.05). CSF NF-L and FABP3 levels were higher in patients with improved outcome (EQ-5D visual analog scale difference > 20). CONCLUSIONS: CSF biomarkers of glial and axonal damage, inflammation, and synaptic changes are altered in symptomatic CSM patients, indicating that axonal injury, astroglial activation, and Aβ dysmetabolism may be present in these individuals. These findings reflect CSM pathophysiology and may aid in prognostication. However, future studies including larger patient cohorts, postoperative biomarker data and imaging, and longer follow-up times are required to validate the present findings.

来源:J Neurosurg Spine,查看原文。版权归原作者所有。

引用

  1. Tsitsopoulos PP, Holmström U, Blennow K, et al. Cerebrospinal fluid biomarkers of glial and axonal injury in cervical spondylotic myelopathy. J Neurosurg Spine. 2021. PMID: 33513577. doi:10.3171/2020.8.SPINE20965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。